PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

NCT00694551 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: Peptide Vaccine
DRUG: Poly IC-LC

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]